Search results for "nephropathy"

showing 10 items of 85 documents

Wine consumption and renal diseases: new perspectives.

2006

Investigations into the relation between wine consumption and kidney disease have been limited. Patients with chronic renal failure show accelerated atherosclerotic damage and, considering the well-known protective effect of wine on the cardiovascular system, moderate wine consumption might be advantageous. Oxidative stress and endothelial dysfunction, which are inter-related, play a role in the pathophysiology of many renal diseases, including acute and chronic renal failure. Ethanol and non-alcoholic wine components, especially polyphenols, influence oxidative balance and endothelial function. Although long-term alcohol abuse has been associated with many renal alterations in humans, in e…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismWinePharmacologyKidneyAntioxidantsNephropathyDiabetic nephropathyPhenolsInternal medicinemedicineHumansEndothelial dysfunctionFlavonoidsWineKidneyNutrition and DieteticsRenal ischemiabusiness.industryPolyphenolsfood and beveragesKidney metabolismmedicine.diseaseOxidative Stressmedicine.anatomical_structureEndocrinologyKidney Failure ChronicEndothelium VascularbusinessOxidation-ReductionKidney disease
researchProduct

Sodium-glucose cotransporter 2 inhibition : towards an indication to treat diabetic kidney disease

2020

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have clearly demonstrated their beneficial effect in diabetic kidney disease (DKD) on top of the standard of care [blood glucose control, renin–angiotensin system blockade, smoking cessation and blood pressure (BP) control], even in patients with overt DKD. However, the indication of this drug class is still blood glucose lowering in type 2 diabetic patients with estimated glomerular filtration rate >45mL/min/1.73m2. Based on the new evidence, several scientific societies have emphasized the preferential prescription of SGLT2i for patients at risk of heart failure or kidney disease, but still within the limits set by health authorities. A r…

medicine.medical_specialtyMedicina030232 urology & nephrologyRenal functionReviewsType 2 diabetes030204 cardiovascular system & hematologyDiabetic nephropathy03 medical and health sciences0302 clinical medicineSodium-Glucose Transporter 2Internal medicineDiabetes mellitusDiabetic nephropathiesmedicineChronic renal failureHumansDiabetic NephropathiesDiabetic kidney diseaseESRDSodium-Glucose Transporter 2 InhibitorsTransplantationbusiness.industryType 2 diabetesNefropaties diabètiquesmedicine.diseasePrognosisBlood pressureDiabetes Mellitus Type 2NephrologyHeart failureSodium/Glucose Cotransporter 2Insuficiència renal crònicabusinessSGLT2 inhibitorsKidney disease
researchProduct

Epidemiological, Clinical and Morphological Characteristics of Immunoglobulin a Nephropathy in Latvia

2020

Abstract Immunoglobulin A nephropathy (IgAN) is the most common chronic glomerulopathy with variable clinical manifestations. IgAN diagnostics became possible in Latvia in 2013. The study aim was to describe IgAN manifestations in the Latvian population by analysing epidemiological, clinical, histological data, and reveal factors that might determine the course of the disease. The retrospective, one-centre study included biopsy-proven IgAN patients over a five-year period in the Nephrology Centre at Pauls Stradiņš Clinical University Hospital. Data from inpatient and outpatient medical records were collected. The study included 69 patients with histologically confirmed IgAN (23% of all rena…

medicine.medical_specialtyMultidisciplinaryGeneral interestkidney diseaseSciencekidney biopsyQnephrology030232 urology & nephrologyimmunoglobulin aurologic and male genital diseases03 medical and health sciences0302 clinical medicineImmunologyEpidemiologymedicine030212 general & internal medicineImmunoglobulin A NephropathyglomerulonephritisProceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences.
researchProduct

Is Myeloperoxidase a Key Component in the ROS-Induced Vascular Damage Related to Nephropathy in Type 2 Diabetes?

2013

AbstractIt is still unclear whether microvascular complications of type 2 diabetes correlate with leukocyte-endothelium interactions and/or myeloperoxidase (MPO) levels. In the present study, we found that serum levels of glucose, the rate of ROS and MPO concentration were higher in type 2 diabetic patients. Patients with nephropathy (39.6%) presented higher MPO levels that correlate positively with the albumin/creatinine ratio (r=0.59, p<0.05). In addition, nephropatic patients showed increased leukocyte-endothelium interactions due to an undermining of polymorphonuclear leukocytes (PMN) rolling velocity and increased rolling flux and adhesion, which was accompanied by a rise in levels of …

medicine.medical_specialtyPhysiologyClinical BiochemistryType 2 diabetesmedicine.disease_causeBiochemistryNephropathyProinflammatory cytokinechemistry.chemical_compoundInternal medicinemedicineCell AdhesionHuman Umbilical Vein Endothelial CellsLeukocytesHumansNews & ViewsDiabetic NephropathiesCell adhesionMolecular BiologyCells CulturedGeneral Environmental SciencePeroxidaseCreatininebiologyCell adhesion moleculeCell BiologyMiddle Agedmedicine.diseaseEndocrinologychemistryDiabetes Mellitus Type 2Myeloperoxidasebiology.proteinGeneral Earth and Planetary SciencesCytokinesReactive Oxygen SpeciesCell Adhesion MoleculesOxidative stress
researchProduct

Renal protection by antihypertensive drugs

1998

During the last few years there has been a renewed interest in blood-pressure (BP)-induced kidney damage, owing to a progressive increase in the incidence and prevalence of hypertension and vascular diseases as a cause of end-stage renal disease (ESRD). The need to prevent ESRD demands continued efforts so as to identify early those people with hypertension who are at risk and to provide them with effective antihypertensive therapy. This review analyses what is needed in terms of surrogate endpoints for monitoring kidney damage and what is known about the impact of antihypertensive treatments in reducing the BP burden on the kidney in non-diabetic subjects. Although glomerular filtration ra…

medicine.medical_specialtyPhysiologymedicine.drug_classRenal functionBlood PressureKidneyurologic and male genital diseasesEssential hypertensionNephropathyRisk FactorsInternal medicineInternal MedicinemedicineAlbuminuriaHumansAntihypertensive drugAntihypertensive AgentsKidneyProteinuriabusiness.industrySurrogate endpointmedicine.diseasefemale genital diseases and pregnancy complicationsEndocrinologymedicine.anatomical_structureHypertensionCardiologyKidney Failure ChronicMicroalbuminuriamedicine.symptomCardiology and Cardiovascular MedicinebusinessJournal of Hypertension
researchProduct

Urinary Albumin Excretion

2005

During the past few years, a subtle increase in urinary albumin excretion (UAE) not detectable by routine methods, microalbuminuria, has become a prognostic marker for cardiovascular and/or renal risk in diabetic and nondiabetic subjects. Consequently, microalbuminuria assessment is now recommended in a risk stratification strategy not only in diabetic subjects but also for hypertension management. Microalbuminuria is defined as UAE from 30 to 300 mg/24 hours or equivalent amounts using timed overnight or spot urine samples (Table). The definition comes from studies that have established its value as a marker of risk for nephropathy in diabetic subjects. When the potential prognostic value …

medicine.medical_specialtyPopulationUrologyRisk AssessmentNephropathyExcretionchemistry.chemical_compoundInternal medicineInternal MedicinemedicineAlbuminuriaHumanseducationCreatinineeducation.field_of_studybusiness.industryMortality ratemedicine.diseaseEndocrinologychemistryCardiovascular DiseasesRelative riskHypertensionCohortMicroalbuminuriabusinessHypertension
researchProduct

Diabetic Kidney Disease

2010

Diabetic nephropathy (DN) is the leading cause of chronic kidney disease and end-stage renal disease (ESRD). Patients with diabetic nephropathy have a high burden of cardiovascular morbidity and mortality. Therefore, interventions that reduce the incidence and progression rate of DN will reduce morbidity and mortality rates as well as health care costs. Hyperglycemia and arterial hypertension are the two main risk factors for DN, but even in the presence of hyperglycemia and elevated blood pressure (BP) for long periods, DN develops only in susceptible patients. Family studies have confirmed the presence of hereditary factors in the development of DN. Besides these four key factors, others …

medicine.medical_specialtyProteinuriabusiness.industryMortality rateIncidence (epidemiology)Diseasemedicine.diseaseNephropathyDiabetic nephropathyDiabetes mellitusInternal medicineMedicinemedicine.symptombusinessIntensive care medicineKidney disease
researchProduct

Renal artery denervation for treating resistant hypertension: Definition of the disease, patient selection and description of the procedure

2012

Arterial hypertension is responsible for a significant burden of cardiovascular morbidity and mortality, worldwide. Although several rational and integrated pharmacological strategies are available, the control of high blood pressure still remains largely unsatisfactory. Failure to achieve effective blood pressure control in treated hypertensive patients may have a substantial impact on individual global cardiovascular risk, since it significantly increases the risk of developing hypertension-related macrovascular and microvascular complications. Arterial hypertension is arbitrarily defined as 'resistant' or 'refractory' when the recommended blood pressure goals (clinic blood pressure below…

medicine.medical_specialtySympathetic nervous systemSettore MED/09 - Medicina InternahypertensionDrug ResistanceFemoral arteryRisk AssessmentNephropathyPharmacotherapyRenal ArteryRisk Factorsmedicine.arteryInternal medicinemedicineInternal MedicineHumansArterial PressureRenal arterySympathectomyrenal artery denervationglobal cardiovascular riskantihypertensive therapyAntihypertensive AgentsSettore MED/14 - NefrologiaDenervationrefractory hypertensiontreatmentbusiness.industryPatient SelectionType 2 Diabetes Mellitusresistant hypertensionmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato Cardiovascolaremedicine.anatomical_structureBlood pressureTreatment Outcomeresistant hypertension refractory hypertension renal artery denervation antihypertensive therapy global cardiovascular risk.resistant-hypertension; treatment; hypertensionCardiologyCatheter AblationHypertension treatment; Resistant-hypertension treatment; Antihypertensive Agents; Humans; Hypertension; Patient Selection; Renal Artery; Risk Assessment; Risk Factors; Sympathectomy; Treatment Outcome; Arterial Pressure; Catheter Ablation; Drug Resistance; Internal Medicine; Cardiology and Cardiovascular MedicinebusinessCardiology and Cardiovascular Medicineresistant-hypertension
researchProduct

Fatty liver indexandhepatic steatosis index for prediction ofnon-alcoholic fatty liver disease in type 1 diabetes

2017

Background and Aim Little is known about the diagnostic value of hepatic steatosis index (HSI) and fatty liver index (FLI), as well as their link to metabolic syndrome in type 1 diabetes mellitus. We have screened the effectiveness of FLI and HSI in an observational pilot study of 40 patients with type 1 diabetes. Methods FLI and HSI were calculated for 201 patients with type 1 diabetes. Forty patients with FLI/HSI values corresponding to different risk of liver steatosis were invited for liver magnetic resonance study. In-phase/opposed-phase technique of magnetic resonance was used. Accuracy of indices was assessed from the area under the receiver operating characteristic curve. Results Tw…

medicine.medical_specialtyType 1 diabetesWaistHepatologyReceiver operating characteristicbusiness.industryfungiFatty liverGastroenterologymedicine.diseaseLikelihood ratios in diagnostic testingNephropathy03 medical and health sciences0302 clinical medicineEndocrinology030220 oncology & carcinogenesisInternal medicinemedicine030211 gastroenterology & hepatologyMetabolic syndromeSteatosisbusinessJournal of Gastroenterology and Hepatology
researchProduct

Atrial fibrillation and chronic kidney disease: focus on rivaroxaban

2015

Renal insufficiency increases the risk of stroke and bleeding in atrial fibrillation patients. Although vitamin K antagonists reduce the risk of stroke in patients with moderate renal dysfunction, this observation is less clear in patients with renal impairment. Moreover, the risk of bleeding with vitamin K antagonists increases as renal function worsens. Maintaining international normalized ratio values within therapeutic targets is more difficult in patients with renal dysfunction, and those agents may cause warfarin-related nephropathy and vascular calcification. Rivaroxaban is the only nonvitamin K oral anticoagulant with a dose specifically tested in patients with moderate renal insuff…

medicine.medical_specialtyVitamin Kmedicine.drug_classRenal functionurologic and male genital diseasesNephropathyRivaroxabanInternal medicineAtrial FibrillationmedicineHumansRenal Insufficiency ChronicStrokeAgedRivaroxabanbusiness.industryHealth PolicyWarfarinAnticoagulantsAtrial fibrillationVitamin K antagonistmedicine.diseaseStrokeCardiologyWarfarinbusinessFactor Xa Inhibitorsmedicine.drugKidney diseaseJournal of Comparative Effectiveness Research
researchProduct